Form 4 for HALO HALOZYME THERAPEUTICS, INC.
Accepted 2026-09-11 20:35:17 ET · period of report 2026-09-09 · accession 0001159036-26-000119 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-11 20:35 | 2026-09-09+ | HALO | Torley Helen | Pres AND CEO, Dir | M - OptEx | $18.41 | +60.0K | 787.8K | +8% | +$1.10M |
| DMT | 2026-09-11 20:35 | 2026-09-09+ | HALO | Torley Helen | Pres AND CEO, Dir | S - Sale+OE | $107.28 | -60.0K | 767.8K | -7% | -$6.44M |
| DMT | 2026-09-11 20:35 | 2026-09-09+ | HALO | Torley Helen | Pres AND CEO, Dir | M - OptEx | $18.41 | -60.0K | 81.6K | -42% | -$1.10M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-09 | M | A | 20,000 | $18.41 | 787,780 | D | — | — | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. |
| 2 | Common | Common Stock | 2026-09-09 | S | D | 13,304 | $107.22 | 774,476 | D | — | — | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. (F2) Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.640 to $107.632. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Common | Common Stock | 2026-09-09 | S | D | 6,596 | $107.82 | 767,880 | D | — | — | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. (F3) Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.640 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 4 | Common | Common Stock | 2026-09-09 | S | D | 100 | $108.67 | 767,780 | D | — | — | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. |
| 5 | Common | Common Stock | 2026-09-10 | M | A | 20,000 | $18.41 | 787,780 | D | — | — | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. |
| 6 | Common | Common Stock | 2026-09-10 | S | D | 14,588 | $107.01 | 773,192 | D | — | — | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. (F4) Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.360 to $107.350 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range |
| 7 | Common | Common Stock | 2026-09-10 | S | D | 5,412 | $107.58 | 767,780 | D | — | — | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. (F5) Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.360 to $107.820 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range |
| 8 | Common | Common Stock | 2026-09-11 | M | A | 20,000 | $18.41 | 787,780 | D | — | — | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. |
| 9 | Common | Common Stock | 2026-09-11 | S | D | 15,492 | $107.15 | 772,288 | D | — | — | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. (F6) Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.400 to $107.390. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 10 | Common | Common Stock | 2026-09-11 | S | D | 4,508 | $107.55 | 767,780 | D | — | — | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. (F7) Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.400 to $107.960. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 11 | Derivative | Option to Purchase Common Stock | 2026-09-09 | M | D | 20,000 | $18.41 | 121,552 | D | $18.41 · — to 2028-02-14 | 20,000 Common Stock | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. (F8) Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
| 12 | Derivative | Option to Purchase Common Stock | 2026-09-10 | M | D | 20,000 | $18.41 | 101,552 | D | $18.41 · — to 2028-02-14 | 20,000 Common Stock | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. (F8) Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
| 13 | Derivative | Option to Purchase Common Stock | 2026-09-11 | M | D | 20,000 | $18.41 | 81,552 | D | $18.41 · — to 2028-02-14 | 20,000 Common Stock | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. (F8) Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |